Clinical Trial Update: Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer [NA]

View source ↗

Summary

A clinical trial is currently recruiting patients to evaluate PAL-222 for refractory skin ulcers. Phase information is not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Ulcer

Drugs mentioned

• PAL-222

Snippet

Sponsor: PharmaBio Corporation | Conditions: Refractory Skin Ulcer | NA | Status: RECRUITING